Kura Oncology
Logotype for Kura Oncology Inc

Kura Oncology (KURA) investor relations material

Kura Oncology UBS Global Biopharma Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Kura Oncology Inc
UBS Global Biopharma Conference 2026 summary17 Nov, 2026

KOMZIFTI commercial launch

  • Q3 launch sales $13.9M, up 53% QoQ; ~150 new patient starts, up 35%; ~420 total prescriptions, up 65%; prescribing accounts grew 40%.

  • Uptake drivers cited: efficacy, tolerability, once-daily dosing and ability to combine with concomitant medicines and AML therapies.

  • Physicians’ combination use has grown; most cited use is with venetoclax and azacitidine, with gilteritinib combinations also reported.

  • Management expects continued commercial growth over the next several quarters; estimated relapsed/refractory market is $350M-$400M, with ~six months of therapy expected.

  • Management expects combinations may extend treatment duration, while noting this needs to be confirmed as patients continue therapy.

AML combinations and frontline development

  • ASH plans include relapsed/refractory gilteritinib plus ziftomenib data and frontline quizartinib combinations, including a quizartinib-7+3-ziftomenib quadruplet.

  • For gilteritinib combination data, management highlighted response rates, durability and transplant outcomes; frontline quizartinib dose escalation reached planned levels without dose-limiting toxicities, with a 100% CRc rate in the reported patients.

  • KOMET-017 combines intensive and non-intensive frontline cohorts in one protocol; enrollment was tracking in line with expectations.

  • Initial frontline results are expected in 2028; intensive-chemotherapy accelerated-approval endpoint is MRD-negative CR, with EFS for full approval; non-intensive endpoints are CR and OS, respectively.

  • Management cited ~44% marrow MRD negativity after 7+3 in NPM1-mutant patients and viewed a 10%-15% improvement as meaningful; for Ven-Aza, it cited 70%-80% CR and a potential meaningful 10%-15% boost.

Darlifarnib development

  • FDA alignment supports a 40-patient registrational monotherapy trial in HRAS-mutant salivary gland cancer, a high-unmet-need population; management cited response data exceeding expectations for available therapies.

  • In renal cell carcinoma, the phase I-B cabozantinib combination is expected to complete enrollment in H1 2027, with data in H2 2027; management sees a post-IO second-line opportunity, alongside third-line development.

  • RCC combination data cited 33%-50% response rates and 13-month PFS, versus third-line benchmarks of 20%-30% response and ~eight-month PFS; response near 50% could support moving directly into second line.

  • Management estimated a $900M-$1B third-line RCC market and a multi-billion-dollar second-line opportunity, conditional on data and combination strategy.

  • A pancreatic cancer combination with daraxonrasib is planned; early results may be available in H2 2027. Prior adagrasib combination data were described as encouraging but from small datasets.

  • Management expects neutropenia rates to decrease with prophylaxis; prior events were described as laboratory findings that did not translate into infections.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Kura Oncology earnings date

Logotype for Kura Oncology Inc
Jefferies Global Healthcare Conference18 Nov, 2026
Kura Oncology
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Kura Oncology earnings date

Logotype for Kura Oncology Inc
Jefferies Global Healthcare Conference18 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer in the United States. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.